OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Cancer is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	173
Advancing radiomics from contrast-enhanced mammography in breast cancer	157
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	138
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	137
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	135
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	102
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	102
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment	100
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	99
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	96
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	95
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	89
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	89
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	89
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	88
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	88
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	86
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	83
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	82
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	81
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	80
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	80
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	80
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	79
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	75

Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	75
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	74
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	73
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	71
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	69
Navigating therapeutic strategies: HPV classification in head and neck cancer	68
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	67
Genomic ALK alterations in primary and relapsed neuroblastoma	66
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	66
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	65
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	64
Metabolic adaptations in prostate cancer	63
Metastasis-associated fibroblasts in peritoneal surface malignancies	62
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	61
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	60
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	60
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	59
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	59
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	59
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	58
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	57
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	57
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	57
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	56
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	56
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	55
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	54
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer	53
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	53
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	53
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	53